Life Sciences
Hughes Hubbard works with pharmaceutical, biotechnology and healthcare companies navigating complex legal, regulatory and commercial challenges across highly regulated global markets. We serve as trusted partners to clients throughout the product lifecycle, from development and commercialization to compliance, enforcement and dispute resolution. Applying our deep interdisciplinary experience, our teams counsel life sciences and healthcare companies on mergers and acquisitions, licensing and strategic collaborations, antitrust and competition matters, high‑stakes litigation and arbitration, FDA and food and drug regulation, employment issues and government contracts.
Related News & Insights
View All News & InsightsPatrice Jean Named an IP Star by Managing Intellectual Property Magazine
Patrice Jean was named an “IP Star” by Managing Intellectual Property magazine in the 2025 edition of the magazine’s annual list.
Commerce’s Section 232 Pharmaceutical Investigation: Opportunities for Companies Able to Comment by the May 7, 2025 Deadline
April 17, 2025 – On April 1, Secretary of Commerce Howard Lutnick initiated an investigation “to determine the effects on the national security” of the United States “of imports of pharmaceuticals and pharmaceutical ingredients, and their derivative products.” This includes “both finished generic and non-generic...
Hughes Hubbard Leads ANI Pharmaceuticals’ Acquisition of Alimera Sciences
June 2024 – Hughes Hubbard & Reed announced today that it advised diversified biopharmaceutical company ANI Pharmaceuticals in its acquisition of global pharmaceutical company Alimera Sciences. The transaction, which values Alimera at approximately $381 million in up front consideration, has been approved by both the...
Stay Up to Date
Sign up to receive practical updates, fresh perspectives and helpful guidance delivered straight to your inbox.
Stay connected for our latest news and insights.